Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LTRN
DateTimeSourceHeadlineSymbolCompany
12/09/20248:15AMBusiness WireLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
12/03/20248:00AMBusiness WireLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)NASDAQ:LTRNLantern Pharma Inc
11/26/20248:45AMBusiness WireLantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic LethalityNASDAQ:LTRNLantern Pharma Inc
11/19/20248:00AMBusiness WireLantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
11/07/20244:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
11/07/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
11/07/20244:05PMBusiness WireLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
11/05/20248:00AMBusiness WireStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNASDAQ:LTRNLantern Pharma Inc
10/31/20248:00AMBusiness WireLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
10/23/20248:45AMBusiness WireLantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024NASDAQ:LTRNLantern Pharma Inc
10/21/20248:00AMBusiness WireLantern Pharma to Host & Participate in Two Public Webinars During OctoberNASDAQ:LTRNLantern Pharma Inc
10/15/20249:07AMBusiness WireLantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDANASDAQ:LTRNLantern Pharma Inc
09/23/20248:00AMBusiness WireLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersNASDAQ:LTRNLantern Pharma Inc
08/08/20244:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
08/08/20244:01PMBusiness WireLantern Pharma Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
08/07/20249:31AMBusiness Wire Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024NASDAQ:LTRNLantern Pharma Inc
08/05/20248:00AMBusiness WireLantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient CohortNASDAQ:LTRNLantern Pharma Inc
08/01/20248:00AMBusiness WireLantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
07/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/17/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/10/20248:30AMBusiness WireLantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184NASDAQ:LTRNLantern Pharma Inc
06/17/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
06/12/20247:30AMBusiness WireLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284NASDAQ:LTRNLantern Pharma Inc
06/11/202412:16AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LTRNLantern Pharma Inc
05/24/20244:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
05/24/20244:08PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LTRNLantern Pharma Inc
05/24/20244:06PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LTRNLantern Pharma Inc
05/13/20241:30AMBusiness WireOregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...NASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Your Recent History

Delayed Upgrade Clock